Table 1

Association of enhancer of zeste homolog 2 (EZH2) expression with patients' clinicopathological features in primary hepatocellular carcinomas

VariableEZH2 proteinValidation cohort
Testing cohort
All casesNegative expressionPositive expressionp Value*All casesNegative expressionPositive expressionp Value*
Age (years)0.1040.892
 ≤47.91059 (8.6%)96 (91.4%)618 (13.1%)53 (86.9%)
 >47.910717 (15.9%)90 (84.1%)658 (12.3%)57 (87.7%)
Sex0.7180.510
 Male17422 (12.6%)152 (87.4%)10913 (11.9%)96 (88.1%)
 Female384 (10.5%)34 (89.5%)173 (17.6%)14 (82.4%)
Hepatitis history0.5780.661
 Yes16419 (11.6%)145 (88.4%)10713 (12.1%)94 (87.9%)
 No487 (14.6%)41 (85.4%)193 (15.8%)16 (84.2%)
α-Fetoprotein (ng/ml)0.2100.309
 ≤206711 (16.4%)56 (83.6%)569 (16.1%)47 (83.9%)
 >2014515 (10.3%)130 (89.7%)707 (10.0%)63 (90.0%)
Liver cirrhosis0.6080.064
 Yes13215 (11.4%)117 (88.6%)888 (9.1%)80 (90.9%)
 No8011 (13.8%)69 (86.3%)388 (21.1%)30 (78.9%)
Tumour size (cm)0.0000.017
 ≤55915 (25.4%)44 (74.6%)7614 (18.4%)62 (81.6%)
 >515311 (7.2%)142 (92.8%)502 (4.0%)48 (96%)
Tumour multiplicity0.3260.408
 Single12818 (14.1%)110 (85.9%)8712 (13.8%)75 (86.2%)
 Multiple848 (9.5%)76 (90.5%)394 (10.3%)35 (89.8%)
Differentiation0.2500.362
 Well246 (25.0%)18 (75.0%)164 (25%)12 (75%)
 Moderate12914 (10.9%)115 (89.1%)718 (11.3%)63 (88.7%)
 Poor505 (10.0%)45 (90.0%)334 (12.1%)29 (87.9%)
 Undifferentiated91 (11.1%)8 (88.9%)60 (0%)6 (100%)
Stage0.0000.001
 I2811 (39.3%)17 (60.7%)126 (50.0%)6 (50.0%)
 II608 (13.3%)52 (86.7%)506 (12.0%)44 (88.0%)
 III976 (6.2%)91 (93.8%)503 (6.0%)47 (94.0%)
 IV271 (3.7%)26 (96.3%)141 (7.1%)13 (92.9%)
Vascular invasion0.0750.023
 Yes1089 (8.3%)99 (91.7%)573 (5.3%)54 (94.7%)
 No10417 (16.3%)87 (83.7%)6913 (18.8%)56 (81.2%)
Relapse0.1040.410
 Yes1059 (8.6%)96 (91.4%)434 (9.3%)39 (90.7%)
 No10717 (15.9%)90 (84.1%)8312 (14.5%)71 (85.5%)
  • * χ2 test.

  • Mean age.